Abstract
Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are effective and safe oral incretin-based antihyperglycemic drugs. In preclinical studies, DPP-4 inhibitors have demonstrated cardiovascular benefits, independent of glycemic control, in patients with type-2 diabetes mellitus. Since 2005, various DPP-4 inhibitors (sitagliptin, linagliptin and saxagliptin) have been clinically available in the United States. Since 2013, alogliptin is the 4th approved DPP-4 inhibitor available on the market. Studies have shown that alogliptinis non-inferior to comparator drugs among newly diagnosed type 2 diabetes mellitus patients. Alogliptin can effectively be used as a single agent or as an add-on drug in combination with other glucose lowering drugs with favorable outcomes on glycemic control and HbA1C levels.
Keywords: Alogliptin, antihyperglycemic agents, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1, glucosedependent insulinotropic peptide, incretins, type 2 diabetes mellitus.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus
Volume: 14 Issue: 1
Author(s): Sarmad Said, Azikiwe C. Nwosu, Debabrata Mukherjee and German T. Hernandez
Affiliation:
Keywords: Alogliptin, antihyperglycemic agents, dipeptidyl peptidase-4 inhibitors, glucagon-like peptide-1, glucosedependent insulinotropic peptide, incretins, type 2 diabetes mellitus.
Abstract: Dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) are effective and safe oral incretin-based antihyperglycemic drugs. In preclinical studies, DPP-4 inhibitors have demonstrated cardiovascular benefits, independent of glycemic control, in patients with type-2 diabetes mellitus. Since 2005, various DPP-4 inhibitors (sitagliptin, linagliptin and saxagliptin) have been clinically available in the United States. Since 2013, alogliptin is the 4th approved DPP-4 inhibitor available on the market. Studies have shown that alogliptinis non-inferior to comparator drugs among newly diagnosed type 2 diabetes mellitus patients. Alogliptin can effectively be used as a single agent or as an add-on drug in combination with other glucose lowering drugs with favorable outcomes on glycemic control and HbA1C levels.
Export Options
About this article
Cite this article as:
Said Sarmad, Nwosu C. Azikiwe, Mukherjee Debabrata and Hernandez T. German, Alogliptin; A Review of a New Dipeptidyl Peptidase-4 (DPP-4) Inhibitor for the Treatment of Type 2 Diabetes Mellitus, Cardiovascular & Hematological Disorders-Drug Targets 2014; 14 (1) . https://dx.doi.org/10.2174/1871529X14666140701095849
DOI https://dx.doi.org/10.2174/1871529X14666140701095849 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Gene-Nutrient Interaction in Type 2 Diabetes: An Appraisal of the Role of the Peroxisome Proliferator-Activated Receptor Pathway
Current Pharmacogenomics On Some Physiological Aspects of Ethanol Repercussion on Neural and Cardiorenal Functions
Central Nervous System Agents in Medicinal Chemistry Inhibition of Mitogen-Activated Protein Kinases (MAPKs) as a Strategy to Prevent Intimal Hyperplasia Following Cardiovascular Interventions
Vascular Disease Prevention (Discontinued) Molecular and Biochemical Changes of the Cardiovascular System due to Smoking Exposure
Current Pharmaceutical Design Long Chain n-3 Polyunsaturated Fatty Acids in the Prevention of Allergic and Cardiovascular Disease
Current Pharmaceutical Design Critical Illness in Obstetric Patients: Venous Thromboembolism in Pregnancy
Current Women`s Health Reviews Expansion of Umbilical Cord Blood for Clinical Transplantation
Current Stem Cell Research & Therapy Platelet Oxidative Stress and its Relationship with Cardiovascular Diseases in Type 2 Diabetes Mellitus Patients
Current Medicinal Chemistry Melanocortin Receptors, Melanotropic Peptides and Penile Erection
Current Topics in Medicinal Chemistry The Interplay of Marine Exposure in Gestational Diabetes
Current Women`s Health Reviews Cardiovascular Complications of Obesity
Current Respiratory Medicine Reviews Editorial (Application of a Multidisciplinary Approach to Alzheimers Disease to Develop Novel Drug Targets by Integrating Biomarkers, Imaging, Genetic and Molecular Strategies)
Current Alzheimer Research Dual Inhibition of DPP-4 and Cholinesterase Enzymes by the Phytoconstituents of the Ethanolic Extract of Prosopis cineraria Pods: Therapeutic Implications for the Treatment of Diabetes-associated Neurological Impairments
Current Alzheimer Research Anti-Aging Effect of Metformin: A Molecular and Therapeutical Perspective
Current Pharmaceutical Design Anti-Inflammatory Properties of Drugs from saffron crocus
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Microcirculation Dysfunction: A Possible Mechanism Responsible for Reverse Redistribution in Myocardial Perfusion Imaging?
Current Medical Imaging Editorial: Limited Utility of the Handgrip Test for the Diagnosis of Diabetic Cardiovascular Autonomic Neuropathy: “There’s Time Enough, But None to Spare”
Current Vascular Pharmacology Discovery Approaches for Novel Dyslipidemia Drugs
Current Drug Discovery Technologies Comparison of Vascular Responses to Vasoconstrictors in Human Placenta in Preeclampsia between Preterm and Later Term
Current Pharmaceutical Biotechnology Inhibition of α-amylase Activity by Zn<sup>2+</sup>: Insights from Spectroscopy and Molecular Dynamics Simulations
Medicinal Chemistry